Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2026 08:33 ET | Source: ALK Abello

ALK annoncerer positive fase 2-resultater for tablet til behandling af peanutallergi, som viser tidligt indsættende effekt

Intern viden ALLIANCE fase 2‑studiet demonstrerede proof‑of‑concept efter kun 6 måneders vedligeholdelsesbehandling i en bred patientgruppe bestående af både børn og voksne.Klar dosisafhængig og...
April 20, 2026 08:33 ET | Source: ALK Abello

ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy

Inside Information The ALLIANCE phase 2 trial demonstrated proof-of-concept after only 6 months of maintenance treatment in a broad patient population comprising both children and adults.Clear...
April 15, 2026 06:07 ET | Source: ALK Abello

neffy® approved as the first needle-free anaphylaxis treatment of adults and children in Canada

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites,...
April 08, 2026 16:37 ET | Source: ALK Abello

Indberetning af ledelsens transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til artikel 19 i EU-forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...
April 08, 2026 16:37 ET | Source: ALK Abello

Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
April 01, 2026 04:05 ET | Source: ALK Abello

Tildeling af aktiebaserede langsigtede incitamentsinstrumenter til direktion og ledende medarbejdere

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): I henhold til selskabets vederlagspolitik, som er vedtaget på selskabets ordinære generalforsamling den 16. marts 2026, og i tråd med selskabets sædvanlige...
April 01, 2026 04:05 ET | Source: ALK Abello

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): According to the company’s remuneration policy adopted at the company's Annual General Meeting on 16 March 2026 and in line with the company’s usual practice,...
March 31, 2026 03:01 ET | Source: ALK Abello

EURneffy 1 mg approved across the EU as the first and only needle-free adrenaline treatment for young children (≥15 kg) at risk of anaphylaxis

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...
March 16, 2026 13:37 ET | Source: ALK Abello

Generalforsamling i ALK-Abelló A/S afholdt den 16. marts 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S afholdt ordinær generalforsamling den 16. marts 2026. På generalforsamlingen skete følgende: Årsrapport 2025 blev godkendt, og der blev...
March 16, 2026 13:37 ET | Source: ALK Abello

Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): ALK-Abelló A/S held its Annual General Meeting on 16 March 2026. The Annual General Meeting transacted the following business: Approval of the annual...